AbbVie Reports Second-Quarter 2023 Financial Results : vimar

Reports Second-Quarter Diluted EPS of $1.14 on a GAAP Basis, an Increase of 123.5 Percent; Adjusted Diluted EPS of $2.91, a Decrease of 13.6 Percent; These Results Include an Unfavorable Impact of...

Related Keywords

United Kingdom , British , Lumigan Ganfort , Alphagan Combigan , Richarda Gonzalez , Linzess Constella , Epkinly Tepkinly , Facebook , Committee For Medicinal Products Human Use , Roche Group , Exchange Commission , European Hematology Association , European Congress , Twitter , Boehringer Ingelheim , European Medicines Agency , European Union , Scripps Research , Abbvie Inc , Instagram , Genentech , Drug Administration , Allergan , Reports Second Quarter Diluted , Adjusted Diluted , These Results Include , Unfavorable Impact , Share Related , Milestones Expense , Second Quarter Net Revenues , Reported Basis , Quarter Global Net Revenues , Immunology Portfolio Were , Operational Basis , Global Humira Net Revenues Were , Global Skyrizi Net Revenues Were , Global Rinvoq Net Revenues Were , Hematologic Oncology Portfolio Were , Global Imbruvica Net Revenues Were , Global Venclexta Net Revenues Were , Neuroscience Portfolio Were , Global Botox Therapeutic Net Revenues Were , Global Vraylar Net Revenues Were , Aesthetics Portfolio Were , Global Botox Cosmetic Net Revenues Were , Global Juvederm Net Revenues Were , Milestones Expense Incurred Year To Date Through , Second Quarter , Botox Therapeutic , Botox Cosmetic , Adapted Mayo Score , British Journal , Disease Week , Annual Meeting , Medicinal Products , Human Use , Annual Congress , Allergan Aesthetics , Investor Relations , Private Securities Litigation Reform Act , Quarterly Reports , Ended June , Months Ended June ,